NCT02462161View on ClinicalTrials.gov

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 20, 2015

Primary Completion Date

April 16, 2019

Study Completion Date

April 16, 2019

Conditions
Alzheimer's DiseaseMild Cognitive Impairment
Interventions
DRUG

Insulin aspart

Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.

DRUG

Placebo

Participants will administer placebo two times per day with an intranasal delivery device.

Trial Locations (1)

27157

Wake Forest Baptist Hospital, Winston-Salem

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

General Electric

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT02462161 - Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart | Biotech Hunter | Biotech Hunter